Chronic Lymphocytic Leukemia Clinical Trials
Chronic Lymphocytic Leukemia clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for chronic Lymphocytic Leukemia. Corterve aggregates actively recruiting Chronic Lymphocytic Leukemia studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Chronic Lymphocytic Leukemia studies
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT05091424PHASE1Hoffmann-La RocheChronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRochester, Minnesota
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaNCT07061951PHASE2National Cancer Institute (NCI)Recurrent Chronic Lymphocytic LeukemiaDuarte, California
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyNCT04269902PHASE3National Cancer Institute (NCI)Chronic Lymphocytic LeukemiaBirmingham, Alabama
- A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)NCT07508995PHASE2M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia (CLL)Houston, Texas
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesNCT06528301PHASE1Umoja BiopharmaLymphoma, B-CellDuarte, California
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT05672251PHASE2City of Hope Medical CenterRecurrent Diffuse Large B-Cell LymphomaDuarte, California
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesNCT05006716PHASE1, PHASE2BeOne MedicinesB-cell MalignancyBirmingham, Alabama
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069Alliance for Clinical Trials in OncologyAcute Lymphoblastic LeukemiaAnchorage, Alaska
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)NCT01853631PHASE1Baylor College of MedicineNon-Hodgkin LymphomaHouston, Texas
- Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeNCT06863402PHASE2Roswell Park Cancer InstituteRichter SyndromeBuffalo, New York
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxNCT05724121National Heart, Lung, and Blood Institute (NHLBI)Chronic Lymphocytic Leukemia (CLL)Bethesda, Maryland
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLNCT07321652PHASE3Alliance for Clinical Trials in OncologyChronic Lymphocytic LeukemiaBirmingham, Alabama
Chronic Lymphocytic Leukemia trials by state
Chronic Lymphocytic Leukemia trials by metro
Frequently asked questions
- How do I find recruiting Chronic Lymphocytic Leukemia clinical trials?
- Browse the actively recruiting Chronic Lymphocytic Leukemia studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Chronic Lymphocytic Leukemia clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Chronic Lymphocytic Leukemia clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.